Patents by Inventor Teiko Yamamoto

Teiko Yamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Eye drop with difluprednate for macular edema treatment
    Patent number: 10092514
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: October 9, 2018
    Assignee: YAMAGATA UNIVERSITY
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • EYE DROP WITH DIFLUPREDNATE FOR MACULAR EDEMA TREATMENT
    Publication number: 20180133153
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 17, 2018
    Applicant: YAMAGATA UNIVERSITY
    Inventors: Hidetoshi YAMASHITA, Teiko YAMAMOTO, Sakiko GOTO, Sachi ABE, Eriko KIRII, Atsushi OKUMURA
  • Eye drop with difluprednate for macular edema treatment
    Patent number: 9949926
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 24, 2018
    Assignee: YAMAGATA UNIVERSITY
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • EYE DROP WITH DIFLUPREDNATE FOR MACULAR EDEMA TREATMENT
    Publication number: 20150190340
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventors: Hidetoshi YAMASHITA, Teiko YAMAMOTO, Sakiko GOTO, Sachi ABE, Eriko KIRII, Atsushi OKUMURA
  • EYE DROP WITH DIFLUPREDNATE FOR MACULAR EDEMA TREATMENT
    Publication number: 20110190250
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Application
    Filed: July 14, 2010
    Publication date: August 4, 2011
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • VITREOUS CELL LINE
    Publication number: 20090068744
    Abstract: The present invention provides a vitreous cell line capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the vitreous cell line of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of retinal vitreous diseases, and the development of a drug for the prophylaxis and/or treatment of retinal vitreous diseases. Moreover, the cell line is not only highly useful for the biochemical-physiological studies of the vitreous body, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial vitreous body.
    Type: Application
    Filed: February 13, 2007
    Publication date: March 12, 2009
    Applicants: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Kouichi Nishitsuka, Yoshiko Kashiwagi, Naoki Tojo
  • SCLERAL CELL STRAIN
    Publication number: 20090053812
    Abstract: The present invention provides a scleral cell strain capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the scleral cell strain of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of ophthalmic diseases such as scleral inflammation, and the development of a drug for the prophylaxis and/or treatment of said diseases. Moreover, the cell strain is not only highly useful for the biochemical-physiological studies of the sclera, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial sclera.
    Type: Application
    Filed: February 13, 2007
    Publication date: February 26, 2009
    Applicants: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Yoshiko Kashiwagi